Ambrx raises $52 million

Protein optimization company Ambrx (San Diego, Calif.) raised $52 million in a series C round led by Apposite Capital. New investors Glynn Ventures; Dow Employees' Pension Plan; and Union Carbide Employees' Pension Plan joined existing investors Tavistock Life Sciences; Maverick Capital; 5AM Ventures; Versant Ventures; Aravis Ventures; and CMEA Ventures. Roche Venture Fund also participated under a December deal between Ambrx and Roche (SWX:ROCZ) to develop next-generation proteins and peptides (see BioCentury Extra, Thursday Dec. 8, 2005). ...